AP2013007046A0 - Anticoagulant antidotes - Google Patents

Anticoagulant antidotes

Info

Publication number
AP2013007046A0
AP2013007046A0 AP2013007046A AP2013007046A AP2013007046A0 AP 2013007046 A0 AP2013007046 A0 AP 2013007046A0 AP 2013007046 A AP2013007046 A AP 2013007046A AP 2013007046 A AP2013007046 A AP 2013007046A AP 2013007046 A0 AP2013007046 A0 AP 2013007046A0
Authority
AP
ARIPO
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
Prior art date
Application number
AP2013007046A
Other languages
English (en)
Inventor
Joanne Van Ryn
Keith Canada
Robert Copenhaver
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007046(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2013007046A0 publication Critical patent/AP2013007046A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AP2013007046A 2011-03-30 2012-03-27 Anticoagulant antidotes AP2013007046A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30
PCT/EP2012/055397 WO2012130834A1 (fr) 2011-03-30 2012-03-27 Antidotes aux anticoagulants

Publications (1)

Publication Number Publication Date
AP2013007046A0 true AP2013007046A0 (en) 2013-08-31

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007046A AP2013007046A0 (en) 2011-03-30 2012-03-27 Anticoagulant antidotes

Country Status (22)

Country Link
US (2) US8821871B2 (fr)
EP (1) EP2691156A1 (fr)
JP (1) JP2014515740A (fr)
KR (1) KR20140009437A (fr)
CN (1) CN103476459A (fr)
AP (1) AP2013007046A0 (fr)
AR (1) AR085758A1 (fr)
BR (1) BR112013025031A2 (fr)
CA (1) CA2827787A1 (fr)
CL (1) CL2013002551A1 (fr)
CO (1) CO6771448A2 (fr)
EA (1) EA201301090A1 (fr)
EC (1) ECSP13012997A (fr)
IL (1) IL227653A0 (fr)
MA (1) MA34978B1 (fr)
MX (1) MX2013011092A (fr)
PE (1) PE20140964A1 (fr)
SG (1) SG193552A1 (fr)
TN (1) TN2013000388A1 (fr)
TW (1) TW201302796A (fr)
UY (1) UY33994A (fr)
WO (1) WO2012130834A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252076B1 (fr) 2011-01-14 2019-09-04 The Regents Of The University Of California Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1
PL2785700T3 (pl) 2011-11-29 2016-09-30 Środki odwracające działanie przeciwzakrzepowe
SG10201708143QA (en) * 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
KR102322425B1 (ko) * 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
JP2016539926A (ja) 2013-10-25 2016-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝血薬の解毒剤
EP2980218A1 (fr) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Complexe de thrombine aptamère à utiliser comme antidote à action directe sur les inhibiteurs de la thrombine
EP3784281A4 (fr) * 2018-04-27 2022-02-16 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Thérapie génique in vivo faisant appel à l'administration d'une construction de gène lentiviral

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU676150B2 (en) 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
EP0981548A4 (fr) 1997-04-30 2005-11-23 Enzon Inc Proteines a chaine unique fixant les antigenes capables de glycosylation, production et utilisations de ces dernieres
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
CA2405525A1 (fr) 2000-04-12 2001-10-25 Principia Pharmaceutical Corporation Proteines fusionnees a l'albumine
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003050531A2 (fr) 2001-12-11 2003-06-19 Algonomics N.V. Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
CA2505326A1 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Procede d'administration de polypeptides therapeutiques et polypeptides associes
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
KR20170100071A (ko) 2007-09-28 2017-09-01 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
KR20120050457A (ko) * 2009-08-24 2012-05-18 베링거 인겔하임 인터내셔날 게엠베하 다비가트란 이텍실레이트 과다복용에 대한 활성 차콜에 의한 응급 중재
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑

Also Published As

Publication number Publication date
MA34978B1 (fr) 2014-03-01
MX2013011092A (es) 2013-12-06
TN2013000388A1 (en) 2015-01-20
BR112013025031A2 (pt) 2017-08-01
CO6771448A2 (es) 2013-10-15
CA2827787A1 (fr) 2012-10-04
JP2014515740A (ja) 2014-07-03
SG193552A1 (en) 2013-11-29
US20120276123A1 (en) 2012-11-01
KR20140009437A (ko) 2014-01-22
EA201301090A1 (ru) 2014-05-30
ECSP13012997A (es) 2013-12-31
AR085758A1 (es) 2013-10-23
NZ613543A (en) 2015-07-31
EP2691156A1 (fr) 2014-02-05
CL2013002551A1 (es) 2014-02-14
TW201302796A (zh) 2013-01-16
US8821871B2 (en) 2014-09-02
CN103476459A (zh) 2013-12-25
UY33994A (es) 2012-09-28
PE20140964A1 (es) 2014-08-17
US20140377265A1 (en) 2014-12-25
WO2012130834A1 (fr) 2012-10-04
IL227653A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
HUS1700030I1 (hu) Véralvadásgátló-antidótumok
HK1197201A1 (en) Autoinjector
HK1198581A1 (en) Autoinjector
HK1188159A1 (en) Auto-injector
HK1188158A1 (zh) 自動注射裝置
HK1188156A1 (en) Auto-injector
HK1188157A1 (en) Auto-injector
GB201322812D0 (en) No title
HK1188162A1 (en) Auto-injector
HK1188161A1 (en) Auto-injector
GB201304176D0 (en) No title
IL232694A0 (en) Self-injecting syringe
GB201508422D0 (en) No Title
GB201406982D0 (en) No title
IL232124A0 (en) Automatic injection device
HK1207948A1 (en) Bouncer
GB201405882D0 (en) No title
GB201312107D0 (en) No title
IL227653A0 (en) Anticoagulant antidotes
GB201119167D0 (en) Novel bachteriophages
GB201313383D0 (en) No title
GB201512453D0 (en) No title
GB201411386D0 (en) No title
PL2363040T3 (pl) Regał
GB201503046D0 (en) No title